June 20, 2022— Members of the U.S. House of Representatives from both political parties went to the House floor recently to deliver a historic series of speeches honoring the upcoming 30th anniversary of the 340B drug pricing program and urging their colleagues to defend the program against unlawful attacks by drug companies. The lawmakers’ unified message was that 340B is … [Read more...]
Recapping a Momentous Year for 340B
Dec. 31, 2021– Today is the final day of what might be one of the most eventful years in the history of the 340B drug pricing program. Key developments in the 340B world stood out even amid all the news about a global pandemic, a change in leadership in Washington, and an uneasy economic climate. As we wrap up 2021 and look forward to a new year, we are reflecting on some of … [Read more...]
Bipartisan Congressional Calls to Protect 340B Intensify
Aug. 4, 2021– A pair of lawmakers is working to advance the latest example of bipartisan, pro-340B legislation in Congress. Reps. Abigail Spanberger (D-Va.) and David McKinley (R-W.V.) recently introduced the Preserving Rules Ordered for The Entities Covered Through 340B Act, also known as the PROTECT 340B Act, and are gathering cosponsors from both sides of the political … [Read more...]
New Data May Convince Congress To Close 340B Loophole
March 18, 2021– One of the quieter debates around the 340B drug pricing program is percolating on Capitol Hill as lawmakers consider whether to plug a loophole in the law that costs rural hospitals much-needed resources. Members of Congress from both parties are looking to pass legislation to make a change on this issue. And a recent study in the prestigious journal Health … [Read more...]
340B Providers Contemplate the Challenges Met and Prepare for the Ones Ahead
By Maureen Testoni March 11, 2021– In this pandemic-focused world we all find ourselves in, it seems only fitting that one of my highlights of this past month was getting the chance to meet Fauci. No, I’m not talking about the esteemed Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, who has become a household name over the past … [Read more...]
MedPAC Report Addresses Key 340B Questions
March 18, 2020– A new report from a respected, independent congressional advisory panel sheds light on several of the key questions surrounding the 340B drug pricing program. In its March 2020 report to Congress, the Medicare Payment Advisory Commission (MedPAC) examined whether participation in the 340B program leads to higher drug spending for Medicare patients with five … [Read more...]
Congressional 340B Champion Matsui Defends Program During Hill Hearing
October 18, 2019– Rep. Doris Matsui (D-Calif.), a longtime champion of the 340B drug pricing program, defended the program during a key congressional hearing to consider drug pricing legislation. Yesterday’s House Energy & Commerce Committee meeting to mark up the Lower Drug Costs Now Act of 2019 (H.R. 3) featured the introduction of an amendment that would have limited … [Read more...]